Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Special Protocol Assessments Get Special Focus In Antibiotic Guidance

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's final guidance on non-inferiority studies in antibiotic drug development is little changed from the 2007 draft version, but provides further clarity for sponsors working under an SPA.

You may also be interested in...



Hospital-Acquired Pneumonia Is Life Or Death, FDA Says; Recommends Sole Primary Endpoint

FDA's draft guidance for clinical trials of drugs for hospital-acquired or ventilator-associated bacterial pneumonia is strict, even compared with the draft guidance for community-acquired bacterial pneumonia.

Hospital-Acquired Pneumonia Is Life Or Death, FDA Says; Recommends Sole Primary Endpoint

FDA's draft guidance for clinical trials of drugs for hospital-acquired or ventilator-associated bacterial pneumonia is strict, even compared with the draft guidance for community-acquired bacterial pneumonia.

Hospital-Acquired Pneumonia Is Life Or Death, FDA Says; Recommends All-Cause Mortality As Sole Primary Endpoint

Rigorous enrollment criteria and strict endpoints characterize FDA's new draft guidance on developing drugs for hospital-acquired and ventilator-associated bacterial pneumonia, even compared with the agency's recent draft guidance on developing drugs for community-acquired bacterial pneumonia.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071508

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel